Your shopping cart is currently empty

BIX-01294 is an G9a Histone Methyltransferase inhibitor(IC50 : 1.9 μM).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $34 | In Stock | In Stock | |
| 5 mg | $77 | In Stock | In Stock | |
| 10 mg | $119 | In Stock | In Stock | |
| 25 mg | $218 | In Stock | In Stock | |
| 50 mg | $328 | In Stock | In Stock | |
| 100 mg | $496 | In Stock | In Stock | |
| 200 mg | $675 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $133 | In Stock | In Stock |
| Description | BIX-01294 is an G9a Histone Methyltransferase inhibitor(IC50 : 1.9 μM). |
| Targets&IC50 | G9a:1.9 μM |
| In vitro | BIX-01294 induced caspase-dependent apoptosis in human bladder cancer cells.?BIX-01294 stimulates endoplasmic reticulum stress (ER stress) and up-regulated expression of PMAIP1 through DDIT3 up-regulation.?Furthermore, down-regulation of the deubiquitinase USP9X by BIX-01294 results in downstream reduction of MCL1 expression, leading to apoptosis eventually[1]. |
| Cell Research | On the first day, cells were seeded in 96 well plates.?Twenty-four hours later, BIX-01294 was added at the indicated concentrations in each well.?After treatment by BIX-01294 for another 24 h, we used 10% TCA to immobilize the cells and then evaluated the living cell numbers using the sulforhodamine B assay as previously described[1] |
| Molecular Weight | 490.64 |
| Formula | C28H38N6O2 |
| Cas No. | 935693-62-2 |
| Smiles | N(C=1C2=C(N=C(N1)N3CCN(C)CCC3)C=C(OC)C(OC)=C2)C4CCN(CC5=CC=CC=C5)CC4 |
| Relative Density. | 1.195 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 84.17 mg/mL (171.55 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.73 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.